Sun Pharmaceutical Peer Comparison

NSE: SUNPHARMA | BSE: 524715

₹1,984.80

₹64.80 (3.38%)

As on 31-Aug-2026IST

Market cap

₹4,69,310 Cr

Revenue (TTM)

₹59,911 Cr

P/E Ratio

38.8

P/B Ratio

5.4

Div. Yield

0.8 %

Edit

	Sun Pharmaceutical	Torrent Pharma	Cipla	Zydus Lifesciences	Lupin
Market cap (₹ Cr)	4,69,310	1,89,347	1,14,393	1,15,920	99,593
Revenue (₹ Cr)	59,911	15,723	28,324	28,592	29,967
Net Profit (₹ Cr)	12,172.70	2,156.00	3,364.84	4,492.20	5,551.01
Net Margin (%)	19.41	13.77	11.54	14.92	18.23
RoE (%)	15.65	26.88	10.63	18.78	28.32
Price to Earnings	38.80	86.82	33.94	25.69	18.01
Price-To-Book	5.43	21.10	3.25	4.30	4.18

Income Statement (₹ Cr)

	Sun Pharmaceutical	Torrent Pharma	Cipla	Zydus Lifesciences	Lupin
Operating Revenue	59,910.52	15,723.00	28,324.40	28,591.70	29,966.58
Total Income	62,725.79	15,654.00	29,158.75	30,111.40	30,442.31
Total Expenditure	42,647.50	10,532.00	22,985.32	21,334.70	20,428.27
EBITDA	17,263.02	5,191.00	5,339.08	7,257.00	9,538.31
Depreciation	2,976.02	1,511.00	1,304.52	1,724.60	1,529.37
EBIT	14,287.00	3,680.00	4,034.56	5,532.40	8,008.94
Interest	363.78	634.00	57.37	510.20	452.37
Other Income	2,815.27	-69.00	834.35	1,519.70	475.73
Exceptional Items	-693.57	-110.00	-275.91	-534.80	-557.91
Profit before Tax	16,044.92	2,867.00	4,535.63	6,007.10	7,474.39
Provision for Tax	3,872.22	711.00	1,170.79	1,514.90	1,923.38
Profit after Tax	12,172.70	2,156.00	3,364.84	4,492.20	5,551.01

	Sun Pharmaceutical	Torrent Pharma	Cipla	Zydus Lifesciences	Lupin
Shareholder's Funds	83,570.09	8,389.00	34,431.95	27,111.40	22,448.27
Minority Interest	-21.43	25.00	14.98	-79.70	-22.18
Non-Current Liabilities	2,283.44	18,384.00	962.15	7,112.50	3,200.22
Current Liabilities	22,622.04	8,343.00	7,013.59	15,711.90	12,651.24
Total Liabilities	1,08,407.20	43,613.69	42,342.71	50,672.60	38,146.06

	Sun Pharmaceutical	Torrent Pharma	Cipla	Zydus Lifesciences	Lupin
Non-Current Assets	43,711.29	33,955.00	15,471.21	31,677.20	11,888.82
Current Assets	63,860.29	9,392.00	24,145.86	19,906.10	24,027.38
Total Assets	1,08,407.20	43,613.69	42,342.71	50,672.60	38,146.06
Total Debt*	4,081.61	14,798.24	257.97	11,769.50	5,910.20
Net Current Assets	41,238.25	1,049.00	17,132.27	4,194.20	11,376.14
Contingent Liabilities	1,587.05	379.25	987.37	989.90	1,094.02

	Sun Pharmaceutical	Torrent Pharma	Cipla	Zydus Lifesciences	Lupin
Cash From Operating Activities	12,419.18	3,022.71	3,940.02	2,116.60	7,334.50
Cash Flow from Investing Activities	-11,344.05	-12,712.41	-2,326.13	-8,296.10	-3,864.59
Cash from Financing Activities	-2,512.55	10,150.60	-1,233.65	5,806.90	-845.87
Net Cash Inflow / Outflow	-1,437.42	460.90	380.24	-372.60	2,624.04

	Sun Pharmaceutical	Torrent Pharma	Cipla	Zydus Lifesciences	Lupin
ROCE (%)	19.11	19.27	16.00	21.39	28.86
ROE (%)	15.65	26.88	10.63	18.78	28.32
ROA (%)	12.12	7.27	8.42	10.03	16.43
EBIT Margin (%)	23.85	23.41	14.24	19.35	26.73
Net Margin (%)	19.41	13.77	11.54	14.92	18.23
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Sun Pharmaceutical	Torrent Pharma	Cipla	Zydus Lifesciences	Lupin
Revenue Growth (%)	11.41	32.85	1.85	21.11	28.19
EBIT Growth (%)	8.10	20.66	-33.61	-8.99	77.03
Net Profit Growth (%)	16.92	7.69	-37.77	-3.14	49.13
EPS Growth (%)	10.18	12.04	-33.63	4.31	60.86
Book Value Growth (%)	15.72	10.51	10.59	13.19	30.75

	Sun Pharmaceutical	Torrent Pharma	Cipla	Zydus Lifesciences	Lupin
Price / Earnings	37.16	74.44	31.96	23.72	16.71
Price / Book Value	5.43	21.10	3.25	4.30	4.18
Dividend Yield (%)	0.82	0.76	0.92	0.09	0.83
EV/EBITDA	25.54	38.94	19.79	16.60	10.09
Market Cap (₹ Cr)	4,21,639.92	1,42,851.87	98,797.18	87,643.18	1,05,737.27

	Sun Pharmaceutical	Torrent Pharma	Cipla	Zydus Lifesciences	Lupin
Debt to Equity	0.00	1.39	0.00	0.12	0.07
Short term debt to equity ratio	0.05	0.35	0.00	0.16	0.18
Current Ratio	2.82	1.13	3.44	1.27	1.90
Quick Ratio	2.31	0.75	2.50	0.91	1.42
Interest Coverage	45.11	5.52	80.06	12.77	17.52

	Sun Pharmaceutical	Torrent Pharma	Cipla	Zydus Lifesciences	Lupin
Debtors to sales (%)	25.89	19.28	19.84	18.94	22.04
Asset Turnover	0.60	0.53	0.71	0.64	0.89
Receivable days	89.14	45.41	52.05	33.55	51.23
Inventory Days	67.85	52.67	57.25	33.80	48.93
Payable days	213.72	244.06	115.96	149.82	205.75
Cash Conversion Cycle	-56.72	-145.98	-6.65	-82.46	-105.59

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.